ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 490K)  | Related Articles | Citation Tracking

Clinical Overview
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?
P. F. Buckley 1 , S. M. Stahl 2
  1 Department of Psychiatry, Medical College of Georgia, Augusta, GA and   2 University of California, San Diego, CA, USA
Correspondence to Peter Buckley, Department of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA.
E-mail: pbuckley@mcg.edu
Copyright 2007 The Authors Journal Compilation 2007 Blackwell Munksgaard
KEYWORDS
negative symptoms • measurement • antipsychotic medications
Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?

ABSTRACT

Objective: Negative symptoms of schizophrenia are debilitating and they contribute to poor outcome in schizophrenia. Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest.

Method: A review of the current 'state-of-play' of pharmacological treatments for negative symptoms in schizophrenia.

Results: Treatment results to date have been largely disappointing. The evidence for efficacy of second-generation antipsychotics is reviewed.

Conclusion: The measurement and treatment trials methodology for the evaluation of negative symptoms need additional refinement before therapeutic optimism that better treatments for negative symptoms can be realized.

Accepted for publication December 21, 2006

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1600-0447.2007.00992.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors
Request ReprintReprint Request

Wiley InterScience is a member of CrossRef.

Cross Ref Member

Search in this Title

Acta Psychiatrica Scandinavica

Search by Citation




Go
 

Sign Up Now
Sign Up Now
Special Issue
CPSP

Free Access to Special Issue on BIPOLAR DISORDERS

This special issue of Clinical Psychology: Science and Practice features reviews of current evidence in the study of Bipolar Disorders with emphasis on the contributions of psychological science and implications for evidence-based practice. Commentaries by international experts provide a global, interdisciplinary context.

Read free special issue
Sign Up Now

Sign Up Now

Be the first to know about new research in your field

Sign up for FREE e-alerts from Wiley-Blackwell journals!

Sign Up Now
Special Issue
Personality and Mental Health

Personality and Mental Health
Volume 4
Issue 1


National Institute for Health and Clinical Excellence Guidelines for the Treatment of Antisocial Personality Disorder and Borderline Personality Disorder

Read the Special Issue
FREE online